A methanolic extract of Ganoderma lucidum fruiting body inhibits the growth of a gastric cancer cell line and affects cellular autophagy and cell cycle uri icon


  • Fundaçao para a Ciencia e a Tecnologia (FCT, Portugal) and COMPETE/QREN/EU for providing financial support to this work (research project PTDC/AGR-ALI/110062/2009), CIMO (strategic project PEst-OE/AGR/UI0690/2011), FCT for the grant of R.T.L. (SFRH/BPD/68787/2010) and QREN for the grants of F.S.R. and D.S. (NORTE-07-0124-FEDER-000023). The authors also thank Dr Gabriela Almeida for technical assistance in the screening assays and Prof. Anabela Martins from the Polytechnic Institute of Bragança for confrmation of the identification of G. lucidum samples. IPATIMUP, Associate Laboratory of the Portuguese Ministry of Science, Technology and Higher Education, is partially supported by FCT.
  • Ganoderma lucidum is one of the most extensively studied mushrooms as a functional food and as a chemopreventive agent due to its recognized medicinal properties. Some G. lucidum extracts have shown promising antitumor potential. In this study, the bioactive properties of various extracts of G. lucidum, from both the fruiting body and the spores, were investigated. The most potent extract identified was the methanolic fruiting body extract, which inhibited the growth of a gastric cancer cell line (AGS) by interfering with cellular autophagy and cell cycle.

publication date

  • January 1, 2014